Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes

被引:2
|
作者
Bartsch, Sarah M. [1 ,2 ,3 ]
Weatherwax, Colleen [1 ,2 ,3 ]
Martinez, Marie F. [1 ,2 ,3 ]
Chin, Kevin L. [1 ,2 ,3 ]
Wasserman, Michael R. [4 ,5 ]
Singh, Raveena D. [6 ]
Heneghan, Jessie L. [1 ,2 ,3 ]
Gussin, Gabrielle M. [6 ]
Scannell, Sheryl A. [1 ,2 ,3 ]
White, Cameron [1 ,2 ,3 ]
Leff, Bruce [7 ]
Huang, Susan S. [6 ]
Lee, Bruce Y. [1 ,2 ,3 ,8 ]
机构
[1] CUNY, Ctr Adv Technol & Commun Hlth CATCH, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[2] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[3] CUNY, Artificial Intelligence Modeling Informat Nutr Gui, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[4] Los Angeles Jewish Home, Reseda, CA USA
[5] Calif Assoc Long Term Care Med, Santa Clarita, CA USA
[6] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA USA
[7] Johns Hopkins Univ, Ctr Transformat Geriatr Res, Div Geriatr Med, Sch Med, Baltimore, MD USA
[8] CUNY, New York City Pandem Response Inst PRI, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
基金
美国医疗保健研究与质量局;
关键词
COVID-19; EFFICACY; OUTCOMES;
D O I
10.1017/ice.2024.9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.Design: We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.Results: Under winter 2023-2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in >= 59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (<=$31,906 per QALY) or cost saving (saving <=$18,372) when the severe outcome risk was >= 3 times higher than that of current omicron variants.Conclusions: SARS-CoV-2 testing costs outweighed benefits under winter 2023-2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 50 条
  • [1] Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
    Tulimilli, SubbaRao, V
    Dallavalasa, Siva
    Basavaraju, Chaithanya G.
    Rao, Vinay Kumar
    Chikkahonnaiah, Prashanth
    Madhunapantula, SubbaRao, V
    Veeranna, Ravindra P.
    VACCINES, 2022, 10 (10)
  • [2] Modeling the Effectiveness of Healthcare Personnel Reactive Testing and Screening for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant Within Nursing Homes
    Zipfel, Casey M.
    Paul, Prabasaj
    Gowler, Camden D.
    Reddy, Sujan C.
    Stone, Nimalie D.
    Slifka, Kara Jacobs
    Slayton, Rachel B.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 : S225 - S230
  • [3] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review
    Feng, Wei
    Zong, Wei
    Wang, Feng
    Ju, Shaoqing
    MOLECULAR CANCER, 2020, 19 (01)
  • [4] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
    Synowiec, Aleksandra
    Szczepanski, Artur
    Barreto-Duran, Emilia
    Lie, Laurensius Kevin
    Pyrc, Krzysztof
    CLINICAL MICROBIOLOGY REVIEWS, 2021, 34 (02) : 1 - 32
  • [5] Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2)
    Maveddat, Ashley
    Mallah, Haneen
    Rao, Sanjana
    Ali, Kiran
    Sherali, Samir
    Nugent, Kenneth
    INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2020, 11 (04) : 157 - 178
  • [6] The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
    Davidov-Derevynko, Yana
    Ben Yakov, Gil
    Wieder, Anat
    Segal, Gad
    Naveh, Lior
    Orlova, Natalia
    Gringauz, Irina
    Amit, Sharon
    Mor, Orna
    Klempfner, Robert
    Rahav, Galia
    Ben Ari, Ziv
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E313 - E319
  • [7] The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
    Davidov-Derevynko, Yana
    Ben Yakov, Gil
    Wieder, Anat
    Segal, Gad
    Naveh, Lior
    Orlova, Natalia
    Gringauz, Irina
    Amit, Sharon
    Mor, Orna
    Klempfner, Robert
    Rahav, Galia
    Ben Ari, Ziv
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E313 - E319
  • [9] JMM Profile: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Inglis, Timothy J. J.
    Mathee, Kalai
    JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 70 (03)
  • [10] Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
    Zhang, Chao
    Zhou, Chenliang
    Shi, Li
    Liu, Ge
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (10) : 2366 - 2369